Avacopan (CCX168; CCX-168; Tavneos) is a small-molecule C5aR antagonist that blocks the effects of C5a. It is a medication approved (in Japan in September 2021, and in the United States in October 2021) for use in the treatment of anti-neutrophil cytoplasmic autoantibody-associated vasculitis.

纯度：≥98%

CAS：1346623-17-3